Page last updated: 2024-08-26

peptide elongation factor 2 and Malaria, Falciparum

peptide elongation factor 2 has been researched along with Malaria, Falciparum in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Bagchus, WM; Bezuidenhout, D; Dhingra, SK; Fidock, DA; Giddins, MJ; Khandelwal, A; Marquart, L; McCarthy, JS; Odedra, A; Oeuvray, C; Tappert, A; Webb, L; Webster, R; Yalkinoglu, Ö; Yin, X1
Badolo, L; Dhingra, SK; Fidock, DA; Giddins, MJ; Greco, B; Gumpp, C; Jonat, B; Oeuvray, C; Rottmann, M; Spangenberg, T; Yin, X1

Trials

1 trial(s) available for peptide elongation factor 2 and Malaria, Falciparum

ArticleYear
Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection stu
    The Lancet. Infectious diseases, 2021, Volume: 21, Issue:12

    Topics: Adult; Antimalarials; Double-Blind Method; Female; Humans; Malaria, Falciparum; Male; Middle Aged; Peptide Elongation Factor 2; Plasmodium falciparum; Young Adult

2021

Other Studies

1 other study(ies) available for peptide elongation factor 2 and Malaria, Falciparum

ArticleYear
Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor.
    Antimicrobial agents and chemotherapy, 2020, 03-24, Volume: 64, Issue:4

    Topics: Animals; Antimalarials; Drug Resistance; Drug Therapy, Combination; Hemeproteins; Malaria, Falciparum; Mice; Mice, SCID; Naphthyridines; Peptide Elongation Factor 2; Plasmodium falciparum; Quinolines

2020